Abstract
Background While hypomethylating agents (HMA) are currently used to treat myelodysplastic syndrome (MDS) and patients with cancer, their effects on reactivation and/or upregulation of oncogenes are generally not well elucidated. SALL4 is a known oncogene that plays an important role in MDS. In this study, we examined the impact of HMA on SALL4 methylation and expression.
Methods Paired bone marrow samples from a cohort of MDS patients on the BMT-AZA trial, collected before and after four cycles of azacytidine (AZA) treatment, were used to explore the relationship between changes in SALL4 expression, treatment response and clinical outcome with a follow-up of up to 40 months. No/low-SALL4 expressing leukemic cell lines were used to study the relationship between SALL4 methylation and expression. A novel locus-specific demethylation technology, CRISPR-DNMT1-interacting RNA (CRISPR-DiR), was used to identify the CpG island critical for SALL4 expression.
Results In MDS patients, we noted SALL4 upregulation after AZA treatment in 40% of the cases. Significantly, patients with SALL4 upregulation had a worse outcome. Using CRISPR-DiR, we discovered that demethylation of a 500bp CpG island within the 5’UTR-Exon1-Intron1 region was critical for SALL4 expression. Importantly, in cell lines and patients, we confirmed that HMA treatment led to demethylation of the same CpG region and upregulation of SALL4 expression.
Conclusions CRISPR-DiR was useful to define the critical region important for gene activation. Along with analysis of patient samples, we demonstrated that demethylation and upregulation of an oncogene after HMA treatment can indeed occur and should be further studied.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
EudraCT number 2010-019673-15
Funding Statement
This study was supported by some fundings. The details were described in the part of Acknowledgements.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
BM samples were obtained from 37 newly diagnosed MDS patients enrolled in the BMT-AZA trial (EudraCT number 2010-019673-15). The study was approved by the IRB at University of Roma Tor Vergata
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵° These authors contribute equallyto this work
The authors have declared that no conflict of interest exists.
We updated the content of main manuscript and figures
Data Availability
All data in the main manuscript and supplementary data are available on request
